A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma
Ixazomib is the only oral proteasome inhibitor used in relapsed/refractory myeloma. Cutaneous side effects due to ixazomib have been documented in the literature; however, cutaneous necrotizing vasculitis is extremely rare. We describe a case of a 74-year-old man with relapsed multiple myeloma who w...
Saved in:
Main Authors: | Heather Katz, Mina Shenouda, Deena Dahshan, George Sonnier, Yehuda Lebowicz |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2019/6061484 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cutaneous Necrotizing Vasculitis and Leukopenia in a Cocaine User: Is Levamisole the Culprit?
by: Lara El Khoury, et al.
Published: (2016-01-01) -
Editorial: Cutaneous vasculitis and vasculopathy
by: Erkan Alpsoy, et al.
Published: (2025-02-01) -
Case of Stroke from Cerebral Vasculitis following Carfilzomib, Lenalidomide, and Dexamethasone Therapy in a Patient with Relapsing Multiple Myeloma
by: Deborah Osafehinti, et al.
Published: (2019-01-01) -
Lethal necrotizing granulomatous vasculitis after bariatric surgery and bilateral mammaplasty
by: O. V. Blagova, et al.
Published: (2018-08-01) -
A Rare Cutaneous Manifestation: Leukocytoclastic Vasculitis after Pfizer-BioNTech COVID-19 Vaccination
by: Yaritza Serrano Gomez, et al.
Published: (2022-01-01)